CJC-1295 is a synthetic tetrasubstituted peptide analog of growth hormone-releasing hormone (GHRH), consisting of 30 amino acids. It was designed with amino acid modifications at positions 2, 8, 15, and 27 to improve metabolic stability and resistance to enzymatic degradation, particularly by dipeptidyl peptidase IV (DPP-IV). In preclinical experimental systems, CJC-1295 has been studied for its binding affinity to the GHRH receptor (GHRHR) and its downstream effects on growth hormone secretion pathways. Researchers utilize CJC-1295 in controlled models to investigate pulsatile hormone release kinetics, receptor desensitization dynamics, and neuroendocrine signaling architecture. Laboratory studies report that CJC-1295 exhibits a prolonged pharmacological profile compared to native GHRH, attributed to its structural modifications that reduce susceptibility to proteolytic cleavage. This extended activity window makes it a useful research tool for studying sustained receptor activation and feedback regulation within the growth hormone axis. Molecular Formula: C₁₅₂H₂₅₂N₄₄O₄₂ Molecular Weight: 3367.97 g/mol CAS: 863288-34-0 Supplied exclusively for laboratory research purposes. Not for human consumption.